Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

被引：0

作者：

G Kerdivel

V Chesnais

E Becht

A Toma

N Cagnard

F Dumont

A Rousseau

P Fenaux

S Chevret

N Chapuis

V Boeva

W H Fridman

M Fontenay

O Kosmider

机构：

[1] Institut Cochin,Department Development

[2] Reproduction,undefined

[3] Cancer,undefined

[4] Institut National de la Santé et de la recherche médicale INSERM U1016,undefined

[5] Centre National de la recherche scientifique CNRS UMR8104,undefined

[6] Université Paris Descartes,undefined

[7] Team Computational (Epi-)Genetics of Cancer,undefined

[8] Paris,undefined

[9] France,undefined

[10] Team Normal and pathological hematopoiesis labeled Ligue nationale contre le cancer,undefined

[11] Paris,undefined

[12] France,undefined

[13] INSERM UMR_S1138,undefined

[14] Cancer,undefined

[15] Immune controls and Escape,undefined

[16] Cordeliers Research Center,undefined

[17] Singapore Immunology Network,undefined

[18] Agency for Science,undefined

[19] Technology and Research (A*STAR),undefined

[20] Assistance Publique-Hôpitaux de Paris,undefined

[21] Service d’hématologie clinique et Thérapie Cellulaire,undefined

[22] Hôpital Henri-Mondor,undefined

[23] Plateforme Paris Descartes de Bioinformatique,undefined

[24] Université Paris Descartes,undefined

[25] Plateforme de Génomique,undefined

[26] Institut Cochin,undefined

[27] Assistance Publique-Hôpitaux de Paris,undefined

[28] Service d’hématologie biologique,undefined

[29] Hôpital Cochin,undefined

[30] Assistance Publique-Hôpitaux de Paris,undefined

[31] Service d’hématologie senior,undefined

[32] Hôpital Saint-Louis,undefined

[33] Assistance Publique-Hôpitaux de Paris,undefined

[34] Laboratoire de Biostatistiques et Epidémiologie clinique INSERM UMR-S 717,undefined

[35] Hôpital Saint-Louis,undefined

来源：

Leukemia | 2018年 / 32卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：558 / 562

页数：4

共 50 条

[21] Bone marrow morphology in myelodysplastic syndrome associated with isolated del(5q)
Naresh, Kikkeri N.
Reid, Alistair
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (08) : 609 - 610
[22] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella, Federico
Latagliata, Roberto
Carmosino, Ida
Volpicelli, Paola
Montagna, Chiara
Romano, Angela
Roberto, Amanda
Finsinger, Paola
Mancini, Marco
Breccia, Massimo
Oliva, Esther
Alimena, Giuliana
HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
[23] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
Garcia-Manero, Guillermo
Santini, Valeria
Almeida, Antonio
Fenaux, Pierre
Gatterman, Norbert
Ozawa, Keiya
Goldberg, Stuart L.
Weaver, Jerry
Sugrue, Mary M.
BLOOD, 2016, 128 (22)
[24] Bone Marrow Immunological Changes During Treatment with Lenalidomide In Low and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5Q)
Oliva, Esther Natalie
Nobile, Francesco
Ronco, Francesca
Alati, Caterina
Morabito, Fortunato
Poloni, Antonella
Cortelezzi, Agostino
Spiriti, Maria Antonietta Aloe
Ricco, Alessandra
Volpe, Antonio
Balleari, Enrico
Sanpaolo, Grazia
Breccia, Massimo
Clissa, Cristina
Alimena, Giuliana
Latagliata, Roberto
BLOOD, 2010, 116 (21) : 1205 - 1206
[25] BONE MARROW CYTOKINE CHANGES DURING TREATMENT WITH LENALIDOMIDE IN LOW AND INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITH DEL(5Q)
Oliva, N.
Ronco, F.
Cuzzola, M.
Alimena, G.
Morabito, F.
Spiriti, M. A. Aloe
Galimberti, S.
Cortelezzi, A.
Specchia, G.
Poloni, A.
Ghio, R.
Breccia, M.
Finelli, C.
Iacopino, P.
D'Errigo, Mg
Lagana, C.
Latagliata, R.
Nobile, F.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 381 - 381
[26] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
Komrokji, Rami S.
Al Ali, Najla H.
Padron, Eric
Cogle, Christopher
Tinsley, Sara
Sallman, David
Lancet, Jeffrey E.
Lis, Alan F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
[27] Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA)
Cerchione, Claudio
Catalano, Lucio
Cerciello, Giuseppe
Avilia, Simona
Picardi, Marco
Risitano, Antonio Maria
Pisano, Ida
Alfinito, Fiorella
Pane, Fabrizio
ANNALS OF HEMATOLOGY, 2015, 94 (03) : 531 - 534
[28] Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA)
Claudio Cerchione
Lucio Catalano
Giuseppe Cerciello
Simona Avilia
Marco Picardi
Antonio Maria Risitano
Ida Pisano
Fiorella Alfinito
Fabrizio Pane
Annals of Hematology, 2015, 94 : 531 - 534
[29] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
Kelaidi, Charikleia
Park, Sophie
Brechignac, Sabine
Mannone, Lionel
Vey, Norbert
Dombret, Herve
Aljassem, Lina
Starnatoullas, Aspasia
Ades, Lionel
Giraudier, Setphane
de Botton, Stephane
Mahe, Beatrice
Lepelley, Pascale
Picard, Fracoise
Leroux, Genevieve
Daniel, Marie-Threrese
Bouscary, Didier
Dreyfus, Francois
Fenaux, Pierre
BLOOD, 2006, 108 (11) : 757A - 757A
[30] A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
Fang, Jing
Liu, Xiaona
Bolanos, Lyndsey
Barker, Brenden
Rigolino, Carmela
Cortelezzi, Agostino
Oliva, Esther Natalie
MacBeth, Kyle J.
Komurov, Kakajan
Starczynowski, Daniel T.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →